Effects of telmisartan and valsartan on insulin resistance, visfatin and adiponectin levels in hypertensive patients with metabolic syndrome

Acta Endocrinologica

Volumn 4, Issue 1, 2008, Pages 23-32

  Sarac S ^a   Saraç, Fulden ^b   Tutuncuoglu P ^c  

^a Karsýyaka State Hospital   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adiponectin; Insulin resistance; Metabolic syndrome; Telmisartan; Valsartan; Visfatin

Indexed keywords

EID: 79960424049     PISSN: 18410987     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen and leucocyte count: findings from the third national health and nutrition survey. Atherosclerosis 2003; 108: 420-425.
2. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: the key features of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-422.
3. Modan M, Halkin H, Almong S, Lusky A, Eshkol A, Shefi M, Shitrit A, Modan B. Hyperinsulinemia a link between hypertension obesity an glucose intolerance. J Clin Inves 1985; 75: 809-817.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
5. Meigs JB, Wilson PW, Nathan DM, D'Agustino RB Sr, Williams K, Haffner SM. Prevalance and characteristics of the metabolic syndrome in the san Antonio heart and Framingham offspring studies. Diabetes 2003; 52 2160-2167.
6. Haffner S, Fong D, Hazuda H, Pugh J, Petterson J. Hyperinsulinemia, upper body adiposity and cardiovascular risk factors in nondiabetics. Metabolism 1988; 37: 338-345.
7. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H. Insulin resistance, hyperinsulinemia and blood pressure: role of age and obesity. European group for the study of insulin resistance (EGIR). Hypertension 1997; 30 1144-1149.
8. DeFronzo R, Ferranini E. Insulin resistance a multifaceted syndrome responsible for NIDDIM, obesity, hypertension, dyslipidemia and athersclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
9. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88: 2399 -2403.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 356 -359.
11. Hristova M, Aloe L. Metabolic syndrome -Neurotrophic hypothesis. javascript:AL_get(this, 'jour', 'Med Hypotheses.'); Med Hypotheses 2006; 66: 545-549.
12. Kurtz TW, Gardner DG. Transcription modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension 1988; 32: 380-386.
13. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005; 22: 3-10.
14. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999; 892: 146-154.
15. Matsuda M, Shimomura I. Adipocytokines and metabolic syndrome-molecular mechanism and clinical implication. Nippon Rinsho 2004; 62 1085-1090.
16. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotinstaining method. Pathol Int 1995; 45: 635-641.
17. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-771.
18. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversial, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525-546.
19. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-566.
20. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, Tambascia M, Bouskela E. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics 2006; 61: 433-440.
21. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991; 89: 247-254.
22. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human material athersclerotic wall. Atherosclerosis 1996; 127: 263-271.
23. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002; 105: 564-569.
24. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
25. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, Acikel C, Oguz Y, Yavuz I, Vural A. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton). 2007; 12(2):147-53.
26. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 15: 4-6.
27. Kurtz T. W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator activated receptor-gamma activator. Acta Diabetol 2005; 42: 9-16.
28. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type I receptor blockers induce peroxisome proliferator-activated receptor-g activity. Circulation 2004; 109: 2054-2057.
29. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
30. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30(4): 323-326.
31. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, Komuro R, Shimomura I. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 2007; 359(2):194-201.
32. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmcol 2005; 46: 735-739.
33. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentration in men. Diabetologia 1985; 28: 412-419.
35. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
36. Katovich MJ, Pachori A. Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin. Diabetes Obes Metab 2000; 2: 3-14.
37. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-139.
38. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990; 13: 1109 -1111.
39. Higashiura K, Ura N, Takada T, Li Y, Torii T, Togashi N, Takada M, Takizawa H, Shimamoto K. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance and hypertension in fructose fed rats. J Hypertens 2000; 13: 290-297.
40. Togashi N, Ura N, Higashiura K, Murakami H, Shimamota K. The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000; 18: 1605-1610.
41. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebilhara K, Hayashi T, Hosoda K, Nakao K. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004; 576: 492-497.
42. Mohling M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, Spranger J. Insulin decreases human adiponectin plasma levels. Horm Metab Res (2002) 34: 655-658.
43. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nakamura T, Shimomura I, Matsuzawa Y. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose derived protein. Diabetes 2001; 50: 2094-2099.
44. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM. Synthetic peroxisome proliferator activated receptor γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380.
45. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
46. Karagiannis A, Mikhailidis DP, Athyros VG, Kakafika AI, Tziomalos K, Liberopoulos EN, Florentin M, Elisaf M. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets 2007; 11: 191-205.
47. Fukuhara, M. Matsuda, M. Nishizawa, K. Segawa, M. Tanaka and K. Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin, Science 2005; 307: 426-430.
48. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Blüher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54:2911-2916.